Apexigen, Inc.
http://www.apexigen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apexigen, Inc.
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data
The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
Venture Funding Deals: Orchard Brings Total To $291m
New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Abcam
- Epitomics, Inc.
- Innova Biosciences
- TGR BioSciences